International Journal of Scientific Research and Engineering Development-– Volume 8 Issue 5, Sep-Oct 2025

Available at www.ijsred.com

RESEARCH ARTICLE OPEN ACCESS

A REVIEW ON CONTROLLED DRUG DELIVERY SYSTEMS

*Shaik Imran, *Syed Nishat Ahmad, *Shaik Jasmin, *K Yaswanth,
**Dr L Mohan Krishna

*IV B Pharmacy Student, Department of Pharmaceutics, Nimra College of Pharmacy Vijayawada AP 521456 INDIA
** Project Guide, Department of Pharmaceutics, Nimra College of Pharmacy Vijayawada AP 521456 INDIA
E-Mail: nishatahmad972@gmail.com

Abstract:

Controlled Drug Delivery Systems are innovative approaches designed to administer therapeutic agents at a regulated pace, over a specified duration, and often targeted to a particular site in the body. These systems aim to maximize treatment effectiveness and minimize adverse effects by sustaining optimal drug levels in the bloodstream.

Keywords: Controlled Drug Delivery System, Actions, Treatments, Effects

INTRODUCTION

Controlled Drug Delivery Systems (CDDS) are pharmaceutical technologies designed to release therapeutic agents at a precisely regulated rate, location, and duration. Their primary goals include achieving sustained, targeted, and zero order release, thereby maintaining optimal drug levels within therapeutic windows while minimizing adverse effects. Conventional dosage forms often result in fluctuating drug concentrations, leading to sub therapeutic or toxic levels. By contrast, CDDS reduce dosing frequency, improve compliance, and stabilize pharmacokinetics through mechanisms such as delayed release or controlled diffusion.The evolution of CDDS is traditionally grouped into three generations:

- **First generation (1950–1980) : -** Strategies employing dissolution, diffusion, osmosis, and ion exchange mechanisms mainly in oral and Tran's dermal formulations.
- **Second generation: -** Incorporation of biodegradable polymer matrices and micro or nano particles to deliver proteins, peptides, and enhance targeting efficiency.
- **Third generation: -** Advanced systems featuring poorly water soluble drug delivery, long term non invasive methods self regulated release and stimuli responsive nano carriers.

This review delves into the fundamental mechanisms, material platforms, administration routes, smart stimuli responsive systems, clinical and commercial applications, and the challenges shaping the future of CDDS.

Dosage form = Active Pharmaceutical Ingredient (API) + Excipients/additives



Mechanisms of Controlled Release: -

CDDS are categorized by their release mechanism, each leveraging different scientific principles:

Dissolution Controlled Systems: -

These systems use a drug encased in or coated by slowly dissolving polymers. The reservoir type encapsulates a core with a diffusion barrier the matrix type disperses the drug within a dissolvable matrix. Common in oral and tarn's dermal platforms, these systems rely on the polymer's dissolution rate to control drug release.

Diffusion Controlled Systems: -

Drug release occurs through Fickian diffusion either through an inert polymeric membrane in reservoir systems or from a drug polymer mix in monolithic systems. Release kinetics depends intrinsically on the polymer's diffusion characteristics.

Water Penetration Controlled Systems: -

These include osmotic and swelling controlled systems. OROS, developed by Alza, uses a semi permeable membrane water influx drives uniform drug release through osmotic pressure. This design enables zero order kinetics and has seen notable clinical success despite initial formulation challenges.

Chemically Controlled Systems: -

Such systems rely on bulk or surface erosion of biodegradable polymers like PLGA, poly anhydrides, or by pendant chain linkages, where drugs are cleaved from polymer backbones under specific conditions. Challenges include controlling defect related variability and regulatory hurdles due to new molecular entities formed.

Nano particle Based and Stimuli Responsive Systems: -

Nano carriers introduce precise release control functions like pH, or electrically responsive release. Reduction sensitive nano particles exploit the tumour's reductive microenvironment to trigger drug release during bond cleavage. Electro responsive systems, often based on conducting polymers, change release behaviour under electrical stimuli such as disassembly of layer stacks or induced charge shift enabling on demand activation though challenges in drug loading, release rate, and local tissue effects persist.



Biomaterials and Delivery Platforms: -

Biodegradable Polymers: -

Materials such as PLGA, poly anhydrides, and poly orthocentres are widely used due to controlled degradation, biocompatibility, and tenability. However, defects during synthesis and unpredictable erosion modes can complicate release kinetics. Stimuli responsive or smart polymers, reacting to internal or external signals, enable on demand release in localized contexts like tumour sites or externally triggered therapy.

Cellular and Membrane Based Systems: -

Leveraging biological carriers including erythrocytes, leukocytes, stem cells, and platelets capitalizes on natural immune evasion, circulation longevity, and barrier penetration. Payloads can be internalized or attached to cell surfaces, offering biocompatible sustained release with targeting capabilities challenges include clearance and toxicity management.

Emerging Smart Composite Platforms: -

Innovations include:

- Magnetic electro spun fibbers that, when exposed to alternating magnetic fields heat up and trigger drug release useful for train's dermal pain or oncology applications.
- Thermo responsive hydro gels that respond to temperature shifts to modulate nano particle diffusion and release allowing switch like control over drug retention and mobilization.

Synthetic Polymers	Natural Polymers	Stimuli-Responsive Polymers
Polyhydroxy ethyl methacrylate poly (2-hydroxyethyl methacrylate) Ethyl cellulose Hydroxypropyl methyl cellulose (HPMC) Eudragits Polylactic acid (PLA) Polylactic-co-glycolic acid (PLGA) Polycaprolact	Alginates Starches Dextrans Cellulose Gums (Acacia, Tragacanth, Guar gum) Chitosan Collagen Gelatine Microbial polymers (Polyhydroxy butyrate) Arginine	**pH-responsive:** Polyacids (PLA, Polymethacrylate, Poly aspartate, alginates, polystyrene sulphonic acid) Polybases (Chitosan, poly-L-Lysine, Polyallylamine, Poly ethylene amine, Poly amidoamine dendrimer) **Thermorespon**

Synthetic Polymers	Natural Polymers	Stimuli-Responsive Polymers
one Polyvinyl Pyrrolidone (PVP) Poly methyl methacrylate (PMMA) Poly-(N-Isopropyl acrylamide) (PNIPAM) Poly(ethyleni mine) Cyclodextrin (α, β, γ) Carbomers	derivative s	**sive:** Poly-(N-Isopropyl acrylamide) (PNIPAM) Poly-(N-Vinylcaprolacta m) Poly(N,N-dimethyl acrylamide) Poly (methyl vinyl ether) **Electric responsive:** Sulfonated polystyrenes Poly(thiophene)s Poly(ethyl oxazoline)s **Ultrasound responsive:** Ethylene-vinyl acetate **Light responsive:** Modified poly(acrylamid e)s

Routes of Administration and Clinical Applications: -

Oral Systems: -

These include osmotic pumps and pulsate systems tailored for chromo therapeutic needs delayed release aligning with disease rhythms like asthma or hypertension and targeted colon delivery for conditions like IBD and colon cancer.

Trans dermal Delivery: -

Tran's dermal patches and deformable lipid vesicles help bypass the stratum corneas and deliver drugs systemically or locally, enhancing bioavailability and reducing first pass metabolism.

Inject able and Implantable Platforms: -

Implants and inject able microspheres can provide site directed, sustained therapy. Biodegradable options like liposomal drugs have demonstrated reduced toxicity and improved efficacy.

Pulmonary, Nasal, and Ocular Systems: -

These target localized treatment for respiratory and ocular conditions. Examples include inhalable formulations for asthma, antibiotic impregnated biomaterials for surgery, and ophthalmic inserts for eye diseases.

Benefits, Limitations, and Advancement: -

Advantages: -

- Improved pharmacokinetic control and therapeutic efficacy.
- Enhanced patient compliance due to reduced dosing frequency.
- Lower systemic exposure and side effects.
- Customizable delivery aligned with disease specific needs.

Limitations: -

- Complex manufacturing and high production costs.
- Potential for dose dumping if system integrity is compromised.
- Limited suitability to specific drug types based on molecular or circulatory properties.
- Regulatory hurdles especially for chemically conjugated or biodegradable.

Recent Innovations: -

- Micro fluidic platforms and lab on chip (LOC) devices allow micro scale, on demand, programmable delivery with precision in carrier synthesis and release control.
- Smart stimuli responsive systems, pH responsive hydro gels and liposomes, reduction sensitive carrier's gated systems enable finely tuned release in response to internal or external triggers.
- Green nanotechnology for eco friendly drug carriers offers sustainable synthesis routes.



CONCLUSION

Controlled Drug Delivery Systems represent a transformative leap in pharmacotherapy enabling steadier drug exposure, targeted therapy, and patient centric dosing profiles. The journey from early dissolution based systems to current smart platforms reflects rapid advancements in materials science, biotechnology, and engineering.

Clinical successes such as liposomal formulations and implants demonstrate CDDS's potential, while ongoing innovations from LOC devices to stimuli responsive biomaterials point to increasingly adaptive and personalized treatments.

However, challenges remain ensuring manufacturing scalability, avoiding dose dumping, managing regulatory complexity, and tailoring drugs to appropriate delivery systems.

Looking forward, integrating precision engineering, systems biology, and green nanotechnology will likely redefine CDDS toward safer, smarter, and more sustainable solutions ushering a new era of therapeutic excellence.

AKNOWLEDGEMENTS: The authors are thankful to all those who have helped in writing this article.

REFERENCES

1. Xiong, Y.; Liu, Z.; Wang, Y.; Wang, J.; Zhou, X.; Li, X. Development and Evaluation of a Water-Free In Situ Depot Gel Formulation for Long-Acting and Stable Delivery of Peptide Drug ACTY116. *Pharmaceutics* **2024**, *16*, 620. https://doi.org/10.3390/pharmaceutics16050620.
2. Xiong, Y.; Wang, J.; Zhou, X.; Li, X. The Development of a Stable Peptide-Loaded Long-Acting Injection Formulation through a Comprehensive Understanding of Peptide Degradation Mechanisms: A QbD-Based Approach. *Pharmaceutics* **2024**, *16*, 266. https://doi.org/10.3390/pharmaceutics16020266.
3. Chen, Y.; He, Q.; Lu, H.; Yang, J.; Han, J.; Zhu, Y.; Hu, P. Visualization and correlation of drug release of risperidone/clozapine microspheres in vitro and in vivo based on FRET mechanism. *Int. J. Pharm.* **2024**, *653*, 123885. https://doi.org/10.1016/j.ijpharm.2024.123885.
4. Yang, D.; Li, Z.; Zhang, Y.; Chen, X.; Liu, M.; Yang, C. Design of Dual-Targeted pH-Sensitive Hybrid Polymer Micelles for Breast Cancer Treatment: Three Birds with One Stone. *Pharmaceutics* **2023**, *15*, 1850. https://doi.org/10.3390/pharmaceutics15061580.
5. Ertugral-Samgar, E.G.; Ozmen, A.M.; Gok, O. Thermo-Responsive Hydrogels Encapsulating Targeted Core-Shell Nanoparticles as Injectable Drug Delivery Systems. *Pharmaceutics* **2023**, *15*, 2358. https://doi.org/10.3390/pharmaceutics15092358.
6. Xing, F.; Shen, H.-Y.; Zhe, M.; Jiang, K.; Lei, J.; Xiang, Z.; Liu, M.; Xu, J.-Z.; Li, Z.-M. Nano-Topographically Guided, Biomineralized, 3D-Printed Polycaprolactone Scaffolds with Urine-Derived Stem Cells for Promoting Bone Regeneration. *Pharmaceutics* **2024**, *16*, 204. https://doi.org/10.3390/pharmaceutics16020204.
7. Rekowska, N.; Wulf, K.; Koper, D.; Senz, V.; Seitz, H.; Grabow, N.; Teske, M. Influence of PEGDA Molecular Weight and Concentration on the In Vitro Release of the Model Protein BSA-FITC from Photo Crosslinked Systems. *Pharmaceutics* **2023**, *15*,

1039. https://doi.org/10.3390/pharmaceutics15041039.

8. Shu, L.; Wang, W.; Ng, C.-i.; Zhang, X.; Huang, Y.; Wu, C.; Pan, X.; Huang, Z. A Pilot Study Exploiting the Industrialization Potential of Solid Lipid Nanoparticle-Based Metered-Dose Inhalers. *Pharmaceutics* **2023**, *15*, 866. https://doi.org/10.3390/pharmaceutics15030866.
9. Escobar, K.; Garrido-Miranda, K.A.; Pulido, R.; Naveas, N.; Manso-Silvan, M.; Hernandez-Montelongo, J. Coatings of Cyclodextrin/Citric-Acid Biopolymer as Drug Delivery Systems: A Review. *Pharmaceutics* **2023**, *15*, 296. https://doi.org/10.3390/pharmaceutics15010296.
10. Abla, K.K.; Mneimneh, A.T.; Allam, A.N.; Mehanna, M.M. Application of Box-Behnken Design in the Preparation, Optimization, and In-Vivo Pharmacokinetic Evaluation of Oral Tadalafil-Loaded Niosomal Film. *Pharmaceutics* **2023**, *15*, 173. https://doi.org/10.3390/pharmaceutics15010173.
11. Ahmed, W.; Kuniyan, M.S.; Jawed, A.M.; Chen, L. Engineered Extracellular Vesicles for Drug Delivery in Therapy of Stroke. *Pharmaceutics* **2023**, *15*, 2173. https://doi.org/10.3390/pharmaceutics15092173
12. Varde N.K., Pack D.W. Microspheres for controlled release drug delivery. Expert Opin. Biol. Ther. 2004;4:35–51. doi: 10.1517/14712598.4.1.35.
13. Ding D., Zhu Q. Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mater. Sci. Eng. C Mater. Biol. Appl. 2018;92:1041–1060. doi: 10.1016/j.msec.2017.12.036.
14. Cheng R., Meng F., Deng C., Klok H.-A., Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials. 2013;34:3647–3657. doi: 10.1016/j.biomaterials.2013.01.084.
15. Merino S., Martin C., Kostarelos K., Prato M., Vazquez E. Nanocomposite Hydrogels: 3D Polymer-Nanoparticle Synergies for On-Demand Drug Delivery. ACS Nano. 2015;9:4686–4697. doi: 10.1021/acsnano.5b01433
16. Jacob J., Haponiuk J.T., Thomas S., Gopi S. Biopolymer based nanomaterials in drug delivery systems: A review. Mater. Today Chem. 2018;9:43–55. doi: 10.1016/j.mtchem.2018.05.002.
17. Hajebi S., Rabiee N., Bagherzadeh M., Ahmadi S., Rabiee M., Roghani-Mamaqani H., Tahriri M., Tayebi L., Hamblin M.R. Stimulus-responsive polymeric nanogels as smart drug delivery systems. Acta Biomater. 2019;92:1–18. doi: 10.1016/j.actbio.2019.05.018.
18. FDA. (2021). Drug Development and Approval Process. U.S. Food & Drug Administration. https://www.fda.gov.

